AlphaTON Capital Corp. (Nasdaq: ATON) (“AlphaTON” or the “Company”), the world’s leading public technology company developing the Telegram super app for an addressable market of more than one billion monthly active users, today announced the execution of a binding purchase option agreement with Immunova, LLC (“Immunova”), granting Immunova, or an affiliate, the option to acquire iOx Therapeutics Limited (“iOx”), a subsidiary wholly-owned AlphaTON has focused on the development of iNKT liposomal agonists.
Upon exercise of the option and completion of the acquisition, AlphaTON would be entitled to an upfront cash payment at closing, equity consideration representing 10% of the acquiring entity’s fully diluted equity at the time of exercise, milestone payments of up to $100 million (payable upon achievement of specified milestones), and single-digit royalties on future net sales, subject to the terms of the definitive documentation.
iOx’s lead candidate, PORT-2 (IMM60), a liposomal iNKT cell agonist, was evaluated in patients with advanced melanoma and metastatic NSCLC in the Phase 1/2 IMP-MEL study, conducted in the United States and the United Kingdom (reported as the IMPORT-201 study). Data presented at ASCO and SITC indicated that PORT-2 was well tolerated as monotherapy at all doses tested, with evidence of biomarkers of immune activation and preliminary signs of anti-tumor activity, including shrinkage of multiple lesions in heavily pretreated PD-1 refractory patients.
The transaction allows AlphaTON to unlock value through iOx while retaining a significant stake in the future success of the pipeline through its equity interest, milestone payments and royalty structure.
“Signing this agreement is an important step in unlocking value from iOx while preserving meaningful long-term economic ownership for AlphaTON,” said Brittany Kaiser, Managing Director of AlphaTON Capital. “iOx is a clinically supported, lipid-based, differentiated immune program, and its placement with Immunova enables dedicated execution as part of a targeted development platform. We will continue to advance our mesothelioma program, where we remain on track to deliver TT-4 to the first patient, and we are progressing our new Telegram-driven, AI-driven biotechnology initiative for rare cancers. value across the portfolio with clear priorities and disciplined execution.”
Brian Horsburgh, PhD, CEO of Immunova, said: “We are pleased to partner with AlphaTON on this transaction. The iOx portfolio represents a differentiated lipid-based immune platform, supported by compelling human clinical data and biomarker evidence, well aligned with our deep expertise in lipid science and development. medicines for patients.
The purchase option can be exercised under certain conditions, in particular that of Immunova guaranteeing financing commitments. There can be no assurance that the purchase option will be exercised, that the contemplated transaction will be consummated, or that, if the transaction is consummated, it will be beneficial to AlphaTON. The transaction remains subject to customary closing conditions.
About AlphaTON Capital Corp. (Nasdaq: ATON)
AlphaTON Capital Corp (NASDAQ: ATON) is the world’s first public technology company developing the Telegram super-app, with an addressable market of 1 billion monthly active users. The company delivers a comprehensive hyperscaler strategy across the Telegram ecosystem through a combination of software products, data middleware, AI training assets, and AI infrastructure hardware clusters deploying confidential AI for the Telegram ecosystem.
Through its operations, AlphaTON Capital provides public market investors with institutional-grade exposure to the Telegram ecosystem and its billion-user platform while maintaining the governance standards and reporting transparency of a Nasdaq-listed company. Led by Chief Executive Officer Brittany Kaiser, Executive Chairman and Chief Investment Officer Enzo Villani, and Chief Business Development Officer Yury Mitin, the Company’s activities span network validation and staking operations, Telegram-based application development, and strategic investments in TON-based decentralized financial protocols, gaming platforms, and commercial applications.
AlphaTON Capital, through its legacy businesses, is also advancing first-in-class therapies targeting known checkpoint resistance pathways to achieve durable therapeutic responses and improve patient quality of life. AlphaTON Capital actively engages in the drug development process and provides strategic advice to guide the development of new immunotherapy assets and combinations of assets.
AlphaTON Capital Corp is a company incorporated in the British Virgin Islands and traded on Nasdaq under the symbol “ATON”.
To learn more, please visit
Official AlphaTON Capital Telegram channel:
Forward-looking statements
All statements contained in this press release, other than statements of historical fact, including, without limitation, statements regarding the Company’s business strategy, management’s plans and objectives for future operations and statements preceded, followed by or otherwise including the words “believe”, “expects”, “anticipates”, “intends”, “estimates”, “will”, “may”, “plans”, “potential”, “continue”, or similar expressions or variations of these expressions are statements prospective. Accordingly, forward-looking statements are subject to certain risks and uncertainties, including, but not limited to: the risk that the purchase option may not be exercised or the transaction may not be consummated, the risk that milestone or royalty payments may not be achieved, the uncertainty of the Company’s investment in TON, the uncertainty around the Company’s historical business, the Company’s operating strategy, the Company’s management team, risks related to the Telegram’s platform and ecosystem, the potential impact of markets and other general economic factors. conditions and other factors set forth in “Item 3 – Key Information – Risk Factors” of the Company’s Annual Report on Form 20-F for the fiscal year ended March 31, 2025 and included in the Company’s Form 6-K filed with the Securities and Exchange Commission on September 3, 2025 and January 13, 2026. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it does not Undue reliance should not be placed on these forward-looking statements. as actual results may differ materially from these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company undertakes no obligation to publicly update or revise any forward-looking statements or information, except as required by law.
Investor relations:
John Ragozzino, CFA
(email protected)
(203) 682-8200
Media inquiries:
Richard Laermer
RP RLM
(email protected)
(212) 741-5106 ext. 216
